The Medical Affairs Lead is a scientific and clinical expert that strategically drives and supports the medical objectives of Alnylam in the area of rare diseases (AHP&PH1).
He/she will be accountable to communicate the science and clinical application of RNAi to Healthcare Practitioners (HCPs). He/she will provide support to all functions within the Country to ensure achievement of local objectives, in close collaboration with Global Medical Affairs to maximize patient outcomes by setting and continuously advancing the evidence-based medical standard of care.
He/she is also expected to build strong cross-functional relationships with colleagues in Medical Affairs, Clinical Research, R&D, Patient Advocacy and Commercial Operations, while maintaining full compliance with all relevant company, industry, legal, and regulatory requirements.
The successful candidate will be based in Netherlands or Belgium and will cover Benelux.
Key Responsibilities
- Develop and continuously maintain the highest scientific and medical expertise within the therapeutic area and be acknowledged internally and externally as an expert in this area, developing peer-to-peer scientific relationships with HCPs and giving medical support to the corresponding cross-functional disease area teams.
- Develop and implement a comprehensive Country Medical Affairs Plan and strategy, to support disease awareness, best clinical practice and the overall corporate objectives
- Identify key opinion leaders and cultivate a network of experts for the specific disease areas.
- Initiate and support high impact medical education activities, including congress symposia, hospital meetings and speaker development programs; provide medical and scientific input into the planning and execution of advisory boards.
- Actively engage with Global Medical Affairs and other functions, providing medical leadership within the TA to ensure the effective local implementation of Alnylam strategy and appropriate use of local market intelligence and development opportunities.
- Collaborate with health care professionals to identify opportunities for the development of algorithms and guidelines to facilitate early diagnosis.
- Support the efforts of patient support groups.
- Manage requests for Alnylam product supply in off-label and compassionate use cases in accordance with local and Alnylam procedures.
- Coordinate the timely and appropriate response to Medical Information enquires, utilizing global medical information resources and in line with local regulatory requirements.
- Support the market access team to discuss the burden of illness and relevant clinical trial data during health technology assessment interactions.
- Responsible for country budget in the specific TA and its accuracy.
- Coordinate required medical, legal, and regulatory review and approval of all field documents for distribution or presentation.
- Training internal team members in relevant therapy areas and product training
Require 50-60% travel.
Qualifications
- MD (Medical Doctor) and/or PhD and/or equally academic qualified healthcare professional. Degree in medical/natural science (PhD, MD) is preferred.
- Excellent fluent and verbal English
- Prior experience in rare disease/Orphan drug products strongly preferred.
- Proven basic science and/or clinical background to enable engagement of Health Care Professionals in a scientifically meaningful exchange.
- Good analytical skills as applied to medical, scientific information.
- Experience in medical education and KOL management.
- Effective communication of evidence based scientific information.
- Knowledge of aspects of drug development, GCP and local regulations.
- Ability to work collaboratively and cross-functionally.
- Management and planning skills as well as decision-making and accountability.
About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
